<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO> WSJ870410-0056 </DOCNO><HL> SmithKline Hepatitis Vaccine</HL><DD> 04/10/87</DD><SO> WALL STREET JOURNAL (J)</SO><IN> SKBPHARMACEUTICALS, HOSPITAL SUPPLIES, MANAGEMENT (PHA) </IN><DATELINE> PHILADELPHIA  </DATELINE><TEXT>   SmithKline Beckman Corp. said it received regulatory approval to sell its Engerix-B vaccine in Switzerland and Luxembourg.    The vaccine treats hepatitis B. In December, the pharmaceutical and health products concern received approval to market the genetically engineered vaccine in Belgium. It is already available in Singapore, and SmithKline has licensing applications pending in 40 countries. </TEXT></DOC>